Source: http://www.google.com/patents/US7585647?ie=ISO-8859-1
Timestamp: 2015-03-31 01:12:39
Document Index: 424048738

Matched Legal Cases: ['Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 02702211', 'Application No. 279', 'Application No. 2002', 'Application No. 2003', 'Application No. 200601204', 'Application No. 200601204', 'Application No. 92', 'Application No. 92', 'Application No. 92', 'Application No. 92']

Patent US7585647 - with changed spatial configuration and improved efficacy; preventing or ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThis invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and, therefore, is useful in preventing and treating viral diseases and cancers. This invention also provides...http://www.google.com/patents/US7585647?utm_source=gb-gplus-sharePatent US7585647 - with changed spatial configuration and improved efficacy; preventing or treating viral diseases; also an artificial gene which codes for the interferonAdvanced Patent SearchPublication numberUS7585647 B2Publication typeGrantApplication numberUS 10/928,956Publication dateSep 8, 2009Filing dateAug 26, 2004Priority dateAug 28, 2003Fee statusPaidAlso published asUS8287852, US20050169885, US20100061961Publication number10928956, 928956, US 7585647 B2, US 7585647B2, US-B2-7585647, US7585647 B2, US7585647B2InventorsGuangwen WeiOriginal AssigneeGuangwen WeiExport CitationBiBTeX, EndNote, RefManPatent Citations (49), Non-Patent Citations (100), Referenced by (5), Classifications (8), Legal Events (2) External Links: USPTO, USPTO Assignment, Espacenetwith changed spatial configuration and improved efficacy; preventing or treating viral diseases; also an artificial gene which codes for the interferon US 7585647 B2Abstract
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4462940 *May 18, 1983Jul 31, 1984Cetus CorporationProcess for the recovery of human β-interferon-like polypeptidesUS4672108Jul 3, 1985Jun 9, 1987Hoffmann-La Roche Inc.Crystalline human leukocyte interferonUS4681930Aug 10, 1984Jul 21, 1987Hoffmann-La Roche Inc.Immune interferon and a method for its extraction and purificationUS4695623Dec 12, 1983Sep 22, 1987AmgenConsensus human leukocyte interferonUS4897471Sep 21, 1987Jan 30, 1990AmgenConsensus human leukocyte interferonUS5372808Apr 15, 1992Dec 13, 1994Amgen Inc.Methods and compositions for the treatment of diseases with consensus interferon while reducing side effectUS5441734Feb 25, 1993Aug 15, 1995Schering CorporationCrystalline zinc interferon alpha-2 having monoclinic morphology and specified x-ray diffraction analysisUS5602232Dec 14, 1994Feb 11, 1997Schering CorporationReacting interferon with supersaturated solution of metal acetateUS5710027May 26, 1994Jan 20, 1998Boehringer Ingelheim International GmbhProcess and vector for expressing alpha-interferon in E. coliUS5874304Jan 18, 1996Feb 23, 1999University Of Florida Research Foundation, Inc.Humanized green fluorescent protein genes and methodsUS5972331Dec 22, 1995Oct 26, 1999Schering CorporationCrystalline interferon alpha for pulmonary delivery and method for producing the sameUS5980884Feb 5, 1996Nov 9, 1999Amgen, Inc.Methods for retreatment of patients afflicted with Hepatitis C using consensus interferonUS6087478Jan 23, 1998Jul 11, 2000The Rockefeller UniversityCrystal of fragment of transcription factor, signal transducer and activator of transcription, that diffracts x-rays for resolution of better than 5.0 angstroms; computer modeling; drug design; drug screening of antagonists/agonistsUS6114145Dec 2, 1998Sep 5, 2000Human Genome Sciences, Inc.Nucleic acid encoding a polypeptide having antiviral activity, bone marrow colony formation activity, and can inhibit colony stimulating factor proliferation of a erythroleukemic cell line; for therapy of immune system disordersUS6532437Oct 23, 1996Mar 11, 2003Cornell Research Foundation, Inc.Crystalline frap complexUS6546074Mar 27, 2001Apr 8, 2003Astex Technology LimitedProtein crystal structure and method for identifying protein modulatorsUS6579695Oct 11, 1996Jun 17, 2003President And Fellows Of Harvard CollegePhosphopantetheinyl transferases and uses thereofUS7364724Aug 28, 2003Apr 29, 2008Sichuan Biotechnology Research CenterRecombinant super-compound interferonUS20040115169Dec 31, 2003Jun 17, 2004Chiron CorporationMethods of protein purification and recoveryUS20040202641 *Aug 28, 2003Oct 14, 2004Sichuan Biotechnology Research CenterRecombinant super-compound interferonAU2003248419A1 Title not availableCN1062565CJun 29, 1998Feb 28, 2001深圳九先生物工程有限公司Recombinating haman alpha type composite interferon and preparation process and use thereofCN1098103CApr 15, 1993Jan 8, 2003安姆根有限公司Pharmaceutical use of sympathetic human white-cell interferonCN1099799AMay 26, 1994Mar 8, 1995贝林格尔-英格海姆国际有限公司Process for preparing and purifying alpha-interferonCN1120846AFeb 24, 1994Apr 17, 1996先灵公司Metal-interferon-alpha crystalsCN1186120ADec 24, 1996Jul 1, 1998深圳科兴生物制品有限公司Recombinative human interferon protein as secretory gene in colibacillusCN1217660AJan 13, 1997May 26, 1999安姆根有限公司Method for retreatment of patients afflicted with Hepatitis C using consensus interferonCN1256148ADec 6, 1999Jun 14, 2000天津华立达生物工程有限公司Stable water solution of interferonCN1291198AFeb 4, 1999Apr 11, 2001伊来克萨斯独资有限公司Three-dimesional structures and models of Fc receptors and use thereofCN1375502AOct 25, 2001Oct 23, 2002南京药科大学Polyglycol modified recombinant human interferonCN1384116AMay 16, 2002Dec 11, 2002中国人民解放军第二军医大学New-type alpha-interferonCN1478545AJul 18, 2003Mar 3, 2004中国科学院微生物研究所Use of compound interferon in the treating of SARS diseaseDE4329756A1Sep 3, 1993Mar 9, 1995Boehringer Ingelheim IntProcess for the preparation and purification of alpha-interferonEP0083734B1Dec 3, 1982Mar 5, 1986F. HOFFMANN-LA ROCHE &amp; CO. AktiengesellschaftCrystalline human leukocyte interferonEP0422697A1Apr 25, 1983Apr 17, 1991Amgen Inc.A consensus leukocyte interferon and a gene encoding itEP0736303B1Mar 30, 1996Aug 25, 1999F. Hoffmann-La Roche AgInterferon solutionEP0777495B1Oct 10, 1995Jul 19, 2000Schering CorporationStable, aqueous alfa interferon solution formulationsEP1371373A1Feb 28, 2002Dec 17, 2003Sichuan Biotechnology Research CenterRecombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitorWO1983004053A1Apr 25, 1983Nov 24, 1983Applied Molecular Genetics IncThe manufacture and expression of large structural genesWO1993021229A1Apr 14, 1993Oct 28, 1993Amgen IncMethods and compositions for the treatment of diseases with interferon while reducing side effectsWO1994019373A1Feb 24, 1994Sep 1, 1994Schering CorpMetal-interferon-alpha crystalsWO1997027866A1Jan 13, 1997Aug 7, 1997Amgen IncMethods for retreatment of patients afflicted with hepatitis c using consensus interferonWO1997027886A1Feb 5, 1997Aug 7, 1997St Jude MedicalCalcification-resistant biomaterialsWO1999040117A1Feb 4, 1999Aug 12, 1999Ilexus Pty LimitedTHREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOFWO2001035987A1Nov 17, 2000May 25, 2001Han KyuboemAn aqueous solution formulation of alpha-interferonWO2002080958A1Feb 28, 2002Oct 17, 2002Rongbing GuoRecombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitorWO2005021777A2Aug 26, 2004Mar 10, 2005Huiyangtech Usa IncUses of spatial configuration to modulate protein functionWO2005034853A2Aug 26, 2004Apr 21, 2005Huiyangtech Usa IncUses of interferons with altered spatial structureWO2006134497A2Mar 9, 2006Dec 21, 2006Guangwen WeiUses of recombinant super-compound interferons* Cited by examinerNon-Patent CitationsReference1Advisory Action Before the Filing of an Appeal Brief for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated May 22, 2007.2Alton, K. et al., 1983, "Production characterization and biological effects of recombinant DNA derived human IFN-alpha and IFN-gamma analogs." In: De Maeger E, Schellekens H. eds. The Biology of Interferon System 2nd ed. Amsterdam: Elsevier Science Publishers, p. 119-128.3Amato, Ivan, 2007, "Silent No Longer: Researchers Unearth Another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.4Apeler H, et al. "Expression of natural and synthetic genes encoding herpes simplex virus 1 protease in Escherichia coli and purification of the protein", European Journal Of Biochemistry / Febs. Aug. 1, 1997, vol. 247, No. 3, Aug. 1, 1997, pp. 890-895, XP002318941, ISSN: 0014-2956.5Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.6Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.7Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.8 *Ausubel F.M. et al. Analysis of Proteins. In Short Protocols in Molecular Biology. 4th Ed. 1999. p. 10-1-10-8.9Blatt, L.M. et al., 1996, "The biological activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon," Journal of Interferon and Cytokine Research, 16(7):489-499.10Canadian Office Action for Sichuan Biotechnolgy Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003, Dated Apr. 21, 2008.11Cao Hongpeng, Tao Peizhen. Effect of Anti-HBV of 6 Drugs Include Lamividine. Natl Med J China, 2001,81(16):1004-1007.12Cao, Hongpeng, and Tao, Peizhen, 2001, "Effect of Anti-HBV of 6 Drugs Include Lamividine," Natl. Med. J. China, 81(16):1004-1007.13Chinese Decision About Rejection for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Nov. 12, 2004.14Chinese Decision About the Reexamination for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Oct. 26, 2005.15Chinese First Notification of Examination for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Apr. 18, 2003.16Chinese Fourth Notification of Examination for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Jun. 4, 2004.17Chinese Notification of Patent for Invention for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Oct. 26, 2005.18Chinese Patent No. CN 1062565C for Zhao, et al., Feb. 24, 1999, "Preparation, Method, and Application of Recombinant Human Consensus Interferon."19Chinese Second Notification of Examination for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Oct. 17, 2003.20Chinese Third Notification of Examination for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001, Dated Jan. 2, 2004.21Cinatl et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.22Day, et al., "Engineered Disulfide Bond Greatly Increases Specific Activity of RecombinNT Murine Interferon-beta", Journal of Interferon Res, vol. 12, pp. 139-143 (1992).23Duan et al., "Anti-SARS Virus Activities of Different Recombinant Human Interferons in Cell Culture System," Chinese J. Clin. Virol. 2003, 17(3):205-208.24Duan et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.25EPO Supplementary European Search Report, Application No. EP 02702211, Filed Feb. 28, 2002, Date of completion of the search: Feb. 23, 2005.26European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.0, Filed Sep. 25, 2003, Dated Dec. 14, 2006.27European Supplemental Search Report for Huiyangtech (USA), Inc., Application No. EP 04782529.4, Filed Mar. 24, 2006, Dated Jun. 17, 2008, Date of Completing of the Search: Jun. 3, 2008.28European Supplemental Search Report for Huiyangtech (USA), Inc., Application No. EP 04809634.1, Filed Mar. 26, 2006, Dated Jun. 17, 2008. Date of Completing of the Search: Jun. 10, 2008.29Fei et al., 1999, "Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon alpha and Lamividine," Shandong Medical Journal, 39(11):3-4.30Fei Junhua, Qin Laiyin, Fan Guiling, et al. Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon ? and Lamividine. Shandong Medical Journal, 1999,39(11): 3-4.31Gao et al., 1999, "Treatment of hepatitis virus related pediatric nephritis with IFN-alpha," Academic Journal of Jinlin Hospital, 12(1):24-26.32Gao Yuanfu, Liu Guanglin, Xia Zhengkun, et al. Treatment of hepatitis virus related pediatric nephritis with IFN-?. Academic Journal of Jinlin Hospital, 1999,12(1):24-26.33Guzman Luz-Maria, et al. "Tight regulation, modulation, and high-level expression by vectors containing the arabinose P-BAD promoter", Journal of Bacteriology, vol. 177, No. 14, 1995, pp. 4121-4130, XP002121022, ISSN: 0021-9193.34Heathcote, E.J.L. et al., 1998, "Re-treatment of chronic hepatitis C with consensus interferon," Hepatology 27(4):1136-1143.35Higgins et al., 1983, "Intranasal Interferon as Protection Against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy, 24(5):713-715.36Holland, C.C. and T.L. Wright, 1994, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 3(1).37Huang Wanzhi, et al. "Use of the arabinose pbad promoter for tightly regulated display of proteins on bacteriophage", Gene (Amsterdam), vol. 251, No. 2, Jun. 27, 2000, pp. 187-197, XP004206676, ISSN: 0378-1119.38Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.39Infergen (Interferon alfacon-1) Product Sheet, Amgen, Inc., Issue Date: Nov. 30, 1998.40International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Feb. 15, 2004.41International Search Report for PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2005.42International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.43International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., "Uses of interferons with altered spatial structure," Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.44Japanese Notification of Reasons of Refusal for Sichuan Biotechnology Research Center, Japanese Application No. 2002-578997, Filed Aug. 28, 2003, Dated Jun. 17, 2008.45Klein, M.L. et al., 1998, "Structural characterization of recombinant consensus interferon-alpha," Journal of Chromatography, 454:205-215.46Lang et al., 2002, "Observation on Serology and Histology of Patients with Chronic Hepatitis B after Interferon Treatment," Chin. J. Infect. Dis., 20(2):97-100.47Lang Zhenwei, Han Honglei, Xu Dejun, et al. Observation on Serology and Histology of Patients with Chronic Hepatitis B after Interferon Treatment. Chin J Infet Dis., 2002,20(2):97-100.48Lei Binjun, Lu Yuhong, Qiu Yanqiu, et al. Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon- ?. Chinese Journal of Practical Internal Medicine, 1995,15(3):155-157.49Lei et al., 1995, "Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon-alpha," Chinese Journal of Practical Internal Medicine, 15(3):155-157.50Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.51Nackley, A.G. et al., 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.52Nasoff, et al., "High-Level Expression of Human Genes in E. coli", Expression, vol. 6, No. 2, pp. 10-11 (1999).53Nasoff, M, "High-level expression of human genes in E. coli" Expressions. 1999. vol. 6.2, p. 10-11.54Notice of Allowance and Fee(s) Due notice for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, dated Jul. 26, 2007.55Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) for PCT/IB2006/002340 for Guangwen WEI, Dated Sep. 20, 2007.56Notification of Transmittal of International Preliminary Report on Patentability (Chapter II of the Patent Cooperation Treaty) for PCT/US04/28067 for Huiyangtech (USA), Inc., Dated Mar. 5, 2007.57Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority (International Search Report and Written Opinion included), International Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.58Ozes, O.N. et al., 1992, "A comparison of interferon-con1 with natural recombinant interferons: antiviral, antiproliferative, and natural killer-inducing activities." J. Interferon Res., 12:55-59.59pBAD Expression System, "Tightly Controlled Bacterial Protein Expression," Invitrogen Corp. Publication, 2002.60pBAD/HisA, B, and C; pBAD/Myc-HisA, B, and C, Version F, "Vectors for Dose-Dependent Expression of Recombinant Proteins Containing N- or C-terminal 6x His Tags in E. coli," Catalog Nos. V430-01, V440-01; Invitrogen Corp. Publication, 1997.61PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., Int'l Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.62Pfeffer, L.M., 1997, "Biologic activity of natural and synthetic type 1 interferons," Seminars in Oncology, 24(3 suppl. 9):S9-63-S9-69.63Pyrc, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders-Drug Targets, (7):59-66.64Scagnolari, C. et al., Dec. 2004, "Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons," Antivir. Ther. 9(6): 1003-11.65Schleif, R.S., 1992, "DNA Looping," Ann. Rev. Biochem., 61:199-223.66Schulte-Frohlinde, et al., Feb. 21, 2002, "Different Activities of Type I interferons on Hepatitis B virus core promoter regulated transcription." Cytokine, 17(4): 214-220.67Singapore Certificate of Grant of Patent for Sichuan Biotechnology Research Center, Singapore Application No. 2003-04969, Filed Aug. 28, 2003, Dated Nov. 30, 2005.68Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Apr. 29, 2008.69Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.70Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 11, 2006.71Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, filed Aug. 28, 2003, Dated Dec. 29, 2006.72Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Aug. 30, 2006.73Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.74U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Guangwen Wei.75U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Guangwen Wei.76U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Guangwen Wei.77U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Guangwen Wei.78U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Apr. 3, 2007.79U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Sep. 19, 2007.80U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 22, 2006.81U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 9, 2007.82U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Feb. 9, 2007.83U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 1, 2007.84U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 8, 2006.85U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Nov. 27, 2006.86U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Aug. 23, 2005.87U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 20, 2006.88U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 7, 2007.89U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Sep. 20, 2006.90Wang Xiangye, Li Xuegang. Comparing Effect of Three Drugs on Turning HBeAg to Negative. Qianwei Medical Journal, 1994,11(4):197-198.91Wang, C. et al., May 2006, "Refolding Recombinant Human Granulocyte Colony Stimulating Factor Expressed by E. coli: A Case Study Using the Unit of Simultaneous Renaturation and Purification of Proteins," BioProcess International, 48-53.92Wang, Xiangye, and Li, Xuegang, 1994, "Comparing Effect of Three Drugs on Turning HBeAg to Negative," Qianwei Medical Journal, 11(4):197-198.93Written Opinion of the Australian Patent Office for SG 200601209-0, National Phase under Chapter II Based on PCT/US2004/028067 for Huiyangtech (USA) Inc., Dated Dec. 4, 2007.94Written Opinion of the International Searching Authority for PCT/US04/28068, filed Aug. 26, 2004 for Huiyangtech (USA) Inc., dated Mar. 4, 2005.95Written Opinion of the International Searching Authority for PCT/US2004/028067, Dated Aug. 26, 2004 for Huiyangtech (USA) Inc., Dated Nov. 2, 2005.96Wu, et al., 2003, "A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China." Chinese Medicine Journal, 116(6):811-818.97Yasuda, et al., 2000, "Spectrum of virus inhibition by consensus interferon YM643." Antiviral Chemistry & Chemotherapy, 11:337-341.98Zeng, Zheng et al., Nov. 2000, "Transfer and expression of human interferon-alpha and its effect on HBV inhibition," Chinese Journal of Infectious Disease, 18(4):221-224.99Zhao, Z. et al., 2003, "Description and clinical treatment of an early outbreak of Severe Acute Respiratory Syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol., 52:715-720.100Zheng, B. et al., Jul. 2004, "Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)," J. Interferon Cytokine Res., 24 (7):288-90.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8415151 *Dec 17, 2010Apr 9, 2013Guangwen WeiCrystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofUS8846025 *Dec 16, 2010Sep 30, 2014Guangwen WeiCrystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofUS20110158941 *Dec 17, 2010Jun 30, 2011Guangwen WeiCrystalline recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofUS20120308520 *Dec 16, 2010Dec 6, 2012Sichuan Huiyang Life Science & Technology Corp.Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereofWO2014106492A2 *Jan 7, 2014Jul 10, 2014Superlab Far East LimitedMethods and compositions for treatment of bone, skin, subcutaneous, mucosal and/or submucosal cancer by percutaneous and/or transmucosal administration of interferon* Cited by examinerClassifications U.S. Classification435/69.51, 536/23.52International ClassificationA61K38/21, C12P21/04, C07H21/04, C07K14/555Cooperative ClassificationA61K38/00, C07K14/555Legal EventsDateCodeEventDescriptionFeb 27, 2013FPAYFee paymentYear of fee payment: 4Jun 15, 2010CCCertificate of correctionRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services